{{Rsnum
|rsid=12721627
|Gene=CYP3A4
|Chromosome=7
|position=99768470
|Orientation=minus
|ReferenceAllele=C
|MissenseAllele=G
|GMAF=0.001377
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=CYP3A4
}}[[rs12721627]], also known as 554C>G, 15603C>G or T185S, is a SNP in the [[CYP3A4]] gene.

The [[rs12721627]](G) allele defines the CYP3A4*16 variant.

{{PharmGKB
|RSID=rs12721627
|Name_s=CYP3A4:554C>G, CYP3A4:T185S
|Gene_s=CYP3A4, CYP3A
|Feature=Exon/NonSyn, NA
|Evidence=PubMed ID:19255940
|Annotation=in vitro study; PK: variant shows substrate altered kinetics compared to wild type
|Drugs=midazolam
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110594
}}

{{PharmGKB
|RSID=rs12721627
|Name_s=CYP3A4:T185S; CYP3A4:658 C>G; CYP3A4:185 Thr>Ser; CYP3A4*16A
|Gene_s=CYP3A4, CYP3A
|Feature=Exon/NonSyn, NA
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp3a4/variant.jsp
|Annotation=Part of CYP3A4*16B haplotype that has been shown to alter paclitaxel metabolite levels in Japanese(Asian) cancer patients; defining polymorphism for CYP3A4*16A.
|Drugs=paclitaxel
|Drug Classes=
|Diseases=Neoplasms
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145180
}}

{{PharmGKB
|RSID=rs12721627
|Name_s=CYP3A4*16; CYP3A4:Thr185Ser
|Gene_s=CYP3A4, CYP3A
|Feature=Exon/NonSyn, NA
|Evidence=PubMed ID:19255940
|Annotation=In an in vitro study, baculovius expressed CYP3A4*16 protein showed a 74% decrease in intrinsic clearance of carbamazepine compared to recombinant wild type protein.
|Drugs=carbamazepine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA164728241
}}

{{PMID Auto
|PMID=20082485
|Title=Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}